Table 2 Univariate and multivariate analyses for survival outcomes after recurrence

FIGO stage

 I

ref

 II

1.63 [0.76–3.48]

0.211

 IIIa and IIIb

1.44 [0.41–5.08]

0.571

 IIIc1 and IIIc2

1.76 [0.94–3.31]

0.080

 Histology

0.270

 Squamous

ref

 adeno

0.84 [0.47–1.48]

0.540

 Other

1.59 [0.78–3.21]

0.200

Primary treatment

 Ope

ref

ref

 Ope + Chemo

4.09 [1.46–11.4]

0.007

3.14 [1.05–9.42]

0.041

 Ope + RT or CCRT

4.83 [1.86–12.55]

0.001

4.81 [1.60–14.45]

0.005

 RT or CCRT

4.23 [1.70–10.73]

0.002

4.62 [1.57–13.60]

0.005

Recurrence site

 Local

ref

Included but not significant in final multivariate analysis

 Pelvic LN

2.83 [1.07–7.52]

0.036

 Distal LN

1.51 [0.63–3.60]

0.353

 Distant metastasis

2.68 [1.24–5.81]

0.012

 Multiple metastasis

4.70 [1.99–11.07]

 < 0.001

Diagnosis method at recurrence

 Pap Smear

ref

Included but not significant in final multivariate analysis

 Symptom

12.43 [3.73–41.46]

 < 0.001

 Tumor Marker

4.13 [1.47–11.58]

0.007

 Imaging analysis

2.94 [1.14–7.55]

0.025